Housing body for medical liquid container and process for producing the same
Abstract
This record has no abstract on file.
Term
Term ended
Projected expiry passed 19 April 2026, 0.4 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
15 claims: 2 independent, 13 dependent
- 1REIVINDICAÇÕES 1. Uma embalagem de recipiente de solução de fármaco compreendendo:um recipiente de plástico de solução de fármaco (10), no qual uma solução de fármaco é colocada e selada e que é esterilizado a vapor ou esterilizado a água quente;uma armadilha de oxigénio;e uma saqueta exterior com uma propriedade de barreira contra oxigénio para colocar e selar o recipiente de plástico de solução de fármaco e a armadilha de oxigénio, em que um plástico que forma o recipiente de plástico de solução de fármaco (10) tem uma taxa de transmissão de gás de oxigénio não inferior a 200 cm 3 /m 2 -24h-atm a uma temperatura de 25 °C e com uma humidade de 60% de HR num período de tempo de doze horas após a esterilização a vapor ou a esterilização a água quente, e tem uma taxa de transmissão de gás de oxigénio não superior a 100 cm 3 /m 2 -24h-atm a uma temperatura de 25 °C e com uma humidade de 60% de HR quando a taxa de transmissão de gás de oxigénio se encontra num estado estável.
- 2Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 1, em que a esterilização a vapor é um processo de aquecimento do recipiente de plástico de solução de fármaco (10) durante 10 a 60 minutos numa atmosfera de gás inerte com uma temperatura de 100 a 121 °C e num estado de vapor saturado.
- 3Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 1, em que o plástico que forma o recipiente de plástico de solução de fármaco (10) é uma película de camadas múltiplas com uma camada de selagem (1) constituída por um plástico à base de poliolefina num lado de superfície interior do recipiente de plástico de solução de fármaco (10), uma camada protetora (5) num lado de superfície exterior do recipiente de plástico de solução de fármaco (10), e uma camada intermédia (4) constituída por um plástico à base de poliol entre a camada de selagem (1) e a camada protetora (5).
- 4Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 3, em que o plástico à base de poliol que forma a camada intermédia (4) é um copolímero de álcool de etileno-vinil com um teor de etileno de 10 a 45% em moles.
- 5Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 3, em que, da película de camadas múltiplas, uma taxa de transmissão de vapor de água da totalidade das camadas dispostas no lado de superfície exterior do recipiente de plástico de solução de fármaco (10) relativamente à camada intermédia (4) corresponde a um valor de 1 a 50 g/m 2 -24h a uma temperatura de 25 °C e com uma humidade de 90% de HR.
- 6Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 3, em que a película de camadas múltiplas tem adicionalmente uma camada de baixa absorção de água (3), constituída por um plástico de baixa absorção de água, entre a camada de selagem (1) e a camada intermédia (4).
- 7Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 6, em que o plástico de baixa absorção de água é um polímero de cicloolefina.
- 8Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 1, em que o plástico que forma o recipiente de plástico de solução de fármaco (10) tem uma taxa de transmissão de gás de oxigénio de 500 a 1000 cm 3 /m 2 -24h-atm a uma temperatura de 25 °C e com uma humidade de 60% de HR num período de tempo de doze horas depois de ser submetido a esterilização a vapor ou a esterilização a água quente.
- 9Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 1, em que o plástico que forma o recipiente de plástico de solução de fármaco (10) tem uma taxa de transmissão de gás de oxigénio de 0,5 a 70 cm 3 /m 2 -24h-atm a uma temperatura de 25 °C e com uma humidade de 60% de HR quando a taxa de transmissão de gás de oxigénio se encontra num estado estável.
- 10Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 1, em que o recipiente de plástico de solução de fármaco (10) é constituído por um plástico tal que necessita de pelo menos dois dias para que a taxa de transmissão de gás de oxigénio alcance o estado estável após a esterilização a vapor ou a esterilização a água quente.
- 11Uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 1, em que uma solução de fármaco colocada e selada no recipiente de plástico de solução de fármaco (10) é uma solução de fármaco que contém uma substância facilmente oxidável. 90% de HR.
- 1213. Um método de fabrico de uma embalagem de recipiente de solução de fármaco, em que, após a criação de uma solução de fármaco colocada e selada num recipiente de plástico de solução de fármaco (10) constituído por um plástico com uma taxa de transmissão de gás de oxigénio não inferior a 200 cm 3 /m 2 -24h-atm a uma temperatura de 25 °C e com uma humidade de 60% de HR num período de tempo de doze horas após a esterilização a vapor ou a esterilização a água quente e com uma taxa de transmissão de gás de oxigénio não superior a 100 cm 3 /m 2 -24h-atm a uma temperatura de 25 °C e com uma humidade de 60% de HR quando a taxa de transmissão de gás de oxigénio se encontra num estado estável, o recipiente de plástico de solução de fármaco (10) é esterilizado a vapor ou esterilizado a água quente e, em seguida, o recipiente de plástico de solução de fármaco (10) esterilizado a vapor ou esterilizado a água quente e uma armadilha de oxigénio são colocados e selados numa saqueta exterior com uma propriedade de barreira contra oxigénio.
- 1314. Um método de fabrico de uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 13, em que a esterilização a vapor é um processo de aquecimento do recipiente de plástico de solução de fármaco (10) durante 10 a 60 minutos numa atmosfera de gás inerte com uma temperatura de 100 a 121 °C num estado de vapor saturado.
- 1415. Um método de fabrico de uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 13, em que a saqueta exterior tem uma taxa de transmissão de vapor de água de 0,5 a 30 g/m 2 -24h a uma temperatura de 25 °C e com uma humidade de 90% de HR.
- 1516. Um método de fabrico de uma embalagem de recipiente de solução de fármaco de acordo com a Reivindicação 13, em que, antes de o recipiente de plástico de solução de fármaco (10) e a armadilha de oxigénio serem colocados e selados na saqueta exterior, um espaço entre o recipiente de plástico de solução de fármaco (10) e a saqueta exterior é substituído por um gás inerte.
Independent claims15
301 paragraphs in 3 sections, as filed
DESCRIPTION
CASE FOR MEDICAL LIQUID CONTAINER AND THEIR PRODUCTION PROCESS
Technical Field
This invention relates to a drug solution container package prepared by placing and sealing a drug solution container which is sealed after being filled with a drug solution in an outer sachet and to a method of manufacture thereof. drug solution container packaging.
Background Art
In recent years, lightweight, malleable, simple to handle and easily disposable plastic containers have been widely used as containers for the placement of drug solutions, and as a plastic that forms such a plastic container is often polyethylene, another polyolefin from the point of view of polypropylene or stability with respect to drug solutions and the safety of medicinal products is used.
However, as it is a material with a high oxygen gas transmission rate, necessarily polyolefins are not applications for the proper placement or preservation of drug solutions which are easily subject to oxidative decomposition from the point of view of the invention. quality maintenance of drug solutions, etc.
On the other hand, Patent Document 1 describes an infusion package in which an infusion, consisting of an aqueous solution containing amino acids, is introduced into a primary medical container having a gas transmission property, and the infusion introduced into the primary medical container, is then placed together with an oxygen trap in a secondary packaging container that is substantially impermeable to oxygen.
<td colspan="4">Similarly, the Patent Document</td><td> 2</td><td>describe</td><td>an</td>
<td>film</td><td>in</td><td>solution container</td><td>in</td><td colspan="2">drug with</td><td>an</td>
<td>film</td><td>in</td><td colspan="2">formed inorganic compound,</td><td colspan="2">at least,</td><td>on one</td>
<td>side of</td><td>an</td><td>plastic film and</td><td>what</td><td>has</td><td colspan="2">the following</td>
<td colspan="2">properties</td><td>Physical (1) to (4):</td><td></td><td></td><td></td><td></td>
<td>(D</td><td>an</td><td>baud rate</td><td>gas</td><td>in</td><td>oxygen</td><td>no</td>
<td colspan="2">higher</td><td> at 1 cc / m<sup>2</sup>-24h-atm;</td><td></td><td></td><td></td><td></td>
<td> (2)</td><td>an</td><td colspan="5">moisture transmission rate not exceeding</td>
g / m<sup>2</sup> -24h -atm;
(3) a light transmission of not less than 80%; and (4) a color b value not exceeding 5.
Further, Patent Document 3 describes an infusion container having a gas barrier property and consisting of a resin container with a flexible wall and at least one outlet formed therein, and in which the container wall mentioned above consists of multiple layers which are divided into an inner layer and an outer layer with an intermediate layer of polyvinyl alcohol as a border, the innermost layer mentioned above is a polyolefin layer with a thickness ranging from 50 to 800 µm, and the outer layer mentioned above is provided such that the outer layer mentioned above has a moisture transmission amount So (g / m<sup>2</sup> -24h at 40 ° C and 90% RH) not less than twice the amount of moisture transmission Si (g / m<sup>2</sup> -24h at a temperature of 40 ° C and 90% RH) of the above-mentioned inner layer; and describes an infusion container, wherein the above-mentioned container is packaged together with a drying agent within a package. The same document also describes that in the infusion container mentioned above, the gas barrier property of the container wall recovers immediately even after autoclaving.
Patent Document 1:
Publication of
Japanese patent
Not examined No. 63-275346
Patent Document 2:
Publication of
Japanese patent
Not examined No. 11-285520
Patent Document 3:
Publication of
Patent
Japanese
Not examined No. 10-80464
EP1245217A2 and EP1396249A2 are other examples of drug solution plastic containers. Disclosure of the Invention
Problem to be solved by the Invention
Where, as in the invention described in Patent Document 1, the primary vessel is transmissible from oxygen gas, oxidative degradation of the solution in the primary vessel cannot be prevented if the primary vessel is left to rest after the secondary vessel is Open. In addition, if microbes, etc., are mixed in the drug solution by mistake when another drug solution is mixed in the primary container from the outside, microbial proliferation may be accelerated by oxygen transmission to the primary container from from abroad.
However, as examples of a film of a plastic provided with an oxygen barrier property (hereinafter referred to simply as an oxygen barrier plastic), plastic films using inorganic materials such as plastic films in which silica are known are known. or the alumina is vapor deposited and the plastic films on which an aluminum foil is laminated.
However, in a drug solution container formed using an oxygen barrier plastic film, as in the invention described in Patent Document 2, due to the excellent oxygen barrier property of the film mentioned above, It is inevitable that the contents will be subject to oxidative degradation over time or that the microbes mistakenly mixed in the drug solution will proliferate if the drug solution container is sealed with oxygen in an empty space therein. Accordingly, it is necessary to perform a process of decreasing the amount of oxygen dissolved in a drug solution before introducing and sealing the drug solution in the drug solution container, and a process of replacing the aforementioned void space with nitrogen. or other inert gas and setting replacement rate infinitely close to 100%. This makes the manufacturing equipment large and complex and results in high costs. Furthermore, in the above mentioned oxygen barrier plastic, holes may be formed due to vibration impacts during transport, etc.
In addition, as plastics with an oxygen barrier property, vinylidene polychloride, polyacrylonitrile, polyvinyl alcohols, ethylene vinyl alcohol copolymers, etc. are known, and films formed from such plastics are also provided.
However, since these plastic films are not suitable for heat resistance, impact resistance, malleability, transparency, etc., they are not suitable for disposal by incineration, or may give rise to eluted matter upon contact with a drug solution, they cannot be used properly as they are to form drug solution containers. In particular, polyvinyl alcohols and ethylene vinyl alcohol copolymers have the problem of changing a lot regarding the oxygen barrier property depending on a change in humidity.
However, while Patent Document 3 describes that the gas barrier property of the infusion container recovers immediately after autoclave sterilization, since no consideration is given to oxygen present within the infusion container, the problems of degradation oxidative content over time, proliferation of microbes, etc., are not resolved.
Accordingly, it is an object of this invention to provide a drug solution container package in which degradation of a drug solution, proliferation of microbes, oxygen, etc., which coexist with transmission can be largely prevented. , while maintaining the necessary characteristics of drug solution plastic containers such as heat resistance, impact resistance, malleability, transparency, and resistance against elution of the plastic constituting the material; and providing a method of manufacturing the drug solution container package.
Problem Solving Means
To achieve the above object, this invention provides:
(1) a drug solution container package comprising: a plastic drug solution container in which a drug solution is placed and sealed and which is steam sterilized or hot water sterilized; an oxygen trap; and an outer sachet having an oxygen barrier property for containing and sealing the above-mentioned drug solution plastic container and the above-mentioned oxygen trap, wherein a plastic forming the drug solution plastic container has a rate of of oxygen gas transmission not less than 200 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm at a temperature of 25 ° C and a humidity of 60% RH over a period of twelve hours after steam sterilization or hot water sterilization, and has a non-oxygen gas transmission rate. greater than 100 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm at a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate if (2) a package according to one of said with (1) above container in which the said container a stable state plastic process;
steam sterilization drug solution heating the drug solution to 60 minutes in an above gas atmosphere
121 ° C in a state a package according to said inert container having a temperature of 100 ° C to saturated steam;
A plastic solution drug forming drug solution with (1) above is a multi-layered drug film with a sealing layer consisting of a polyolefin-based plastic on an inner surface side of the container. aforementioned drug solution plastics, a protective layer on an outer surface side of the aforementioned drug solution plastics container, and an intermediate layer consisting of a polyol-based plastic between the above-mentioned sealing layer and the above-mentioned protective layer;
(4) a drug solution container package according to (3), wherein the polyol-based plastic
<td>what</td><td>form</td><td>the layer</td><td colspan="2">mentioned intermediate</td><td colspan="2">above is</td><td>one</td>
<td colspan="2">copolymer</td><td>of alcohol</td><td>of ethylene-</td><td>vinyl with</td><td>one</td><td>content</td><td>in</td>
<td colspan="2">ethylene from</td><td colspan="2">10 to 45 mole%;</td><td></td><td></td><td></td><td></td>
<td> (5)</td><td colspan="2">a pack of</td><td>container</td><td>of solution</td><td>in</td><td colspan="2">drug</td>
<td>in</td><td>wake up</td><td>with (3),</td><td>Fall</td><td>film</td><td>in</td><td colspan="2">layers</td>
mentioned above, a water vapor transmission rate of all layers disposed on the outer surface side of the above-mentioned drug solution plastic container relative to the above-mentioned intermediate layer is 1 to 50 g / m<sup>2</sup> -24h at a temperature of 25 ° C and a humidity of 90% RH;
(6) a drug solution container package according to (3), wherein the aforementioned multilayer film additionally has a low water absorption layer comprising a low water absorption plastic between the layer sealing agent mentioned above and the intermediate layer mentioned above;
(7) a drug solution container package according to (6), wherein the low water absorption plastic mentioned above is a cycloolefin polymer;
(8) a drug solution container package according to (1), wherein the plastic forming the drug solution plastic container mentioned above has an oxygen gas transmission rate of 500 to 1000 cm.<sup>3</sup>/ m<sup>2</sup>-2 4h-atm at a temperature of 25 ° C and a humidity of 60% RH within a time period of twelve hours after steam sterilization or hot water sterilization;
(9) a drug solution container package according to (1), wherein the plastic forming the drug solution plastic container mentioned above has an oxygen gas transmission rate of 0.5 to 70 cm.<sup>3</sup>/ m<sup>2</sup>-24h-atm at a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate is in a stable state;
(10) a drug solution container package according to (1), wherein the aforementioned drug solution plastic container is one of such plastics which needs at least two days for the rate of oxygen gas transmission reaches steady state after steam sterilization or hot water sterilization;
(11) a drug solution container package according to (1), wherein a drug solution placed and sealed in the aforementioned drug solution plastic container is a drug solution containing an easily oxidizable substance;
(12) a drug solution container package according to (1), wherein the above-mentioned outer sachet has a water vapor transmission rate of 0.5 to 30 g / m<sup>2</sup>-24h at a temperature of 25 ° C and a humidity of 90% RH;
(13) a method of manufacturing a container package creating one in a container consisting of a transmission of cm<sup>3</sup>/ m<sup>2</sup>-24h-atm the drug solution, in which, placed plastic solution oxygen plastic temperature drug
HR within a period of hours after steam sterilization or solution with a gas at 60% humidity after sealed drug at a rate of not less than 25 ° C and with
200 twelve times hot-water sterilization, and with an oxygen gas transmission rate not exceeding 100 cm<sup>3</sup>/ m<sup>2</sup>At -24h-atm at a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate is in a stable state, the drug solution plastic container is steam sterilized or sterilized to hot water and then the steam sterilized or hot water sterilized drug solution plastic container and an oxygen trap are placed and sealed in an outer sachet with an oxygen barrier property;
(14) A method of manufacturing a drug solution container package according to (13), wherein the above-mentioned steam sterilization is a process of heating the above-mentioned drug solution plastic container for 10 to 60 hours. minutes in an inert gas atmosphere at a temperature of 100 to 121 ° C in a saturated vapor state;
(15) A method of manufacturing a drug solution container package according to (13), wherein the above-mentioned outer sachet has a water vapor transmission rate of 0.5 to 30 g / m<sup>2</sup> -24h at a temperature of 25 ° C and a humidity of 90% RH; and (16) a method of manufacturing a drug solution container package according to (13), wherein, before the aforementioned drug solution plastic container and the aforementioned oxygen trap are placed and sealed In the above-mentioned outer sachet, a space between the above-mentioned drug solution plastic container and the above-mentioned outer sachet is replaced by an inert gas.
In this invention, an oxygen gas transmission rate (O<sub>2</sub>GTR) of a plastic is measured according to the
Equal Pressure Method B
Equal Pressure Method) as defined in JIS K 712 6-<sub>19</sub>87
Testing Method for Gas
Transmission Rate through Plastic Film and Sheeting, and a water vapor transmission rate from a plastic is measured according to the Humidity sensor method A defined in JIS K 7 12 9-1992 Testing methods for water vapor transmission rate of plastic film and sheet (instrument method).
In this invention, the following is defined as oxygen gas transmission rates of the plastic forming the drug solution plastic container:
(a) a value measured after subjecting the plastic to steam sterilization [heating in an atmosphere in a saturated vapor state; steam sterilization, or high pressure steam sterilization (autoclave, for example) or hot water sterilization (sterilization in a hot water bath or hot water spray sterilization, for example) and remove water on the surface of the plastic steam sterilized or hot-water sterilized and leave the plastic to stand until it has cooled to a temperature of 25 ° C and a humidity of 60% RH (generally medium at room temperature and relatively moderate humidity) within twelve hours after steam sterilization or hot water sterilization; and (b) a value measured at a temperature of 25 ° C and a humidity of 60% RH in the state in which a change over time of an oxygen gas transmission rate, i.e. Oxygen gas transmission rate is in a stable state.
The oxygen gas transmission rate mentioned above preferably corresponds to the value measured within a time period of eight hours after steam sterilization or hot water sterilization, and more preferably to the value measured within a time period of six hours after sterilization. steam or hot water sterilization. Normally, an interval of approximately four hours is required for a temperature of a plastic subjected to steam sterilization or hot water sterilization to fall to the oxygen gas transmission rate measurement temperature of 25 ° C leaving the plastic resting. until cool.
Also, the above mentioned steam sterilization or hot water sterilization is preferably performed in an atmospheric pressure or in a pressurized atmosphere with a barometric pressure of not more than 4000 hPa, and more preferably in a pressurized atmosphere with a barometric pressure of 2000 to 3500 hPa.
The steady state mentioned above refers to a state in which a change over time of an oxygen gas transmission rate (an oxygen gas transmission rate under fixed conditions, such as a temperature of 25 ° C and a 60% RH) corresponds to ± 5% per hour and more preferably ± 3% per hour.
Normally, to cause an oxygen gas transmission rate of a plastic used to form a drug solution container to return to a stable state after steam sterilization or hot water sterilization leaving the plastic to stand until it cools down. Generally, an interval of two days, preferably three days, and more preferably four days is required after steam sterilization or hot water sterilization.
Effect of the Invention
Since the drug solution plastic container of the drug solution container package according to this invention is comprised of so-called low oxygen gas transmission plastic with an oxygen gas transmission rate not exceeding 100 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm in the environment with a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate is stable even when the drug solution container is left to stand after opening the outer sachet of the drug solution container package mentioned above according to this invention, Oxygen transmission to the drug solution container may be prevented to prevent oxidative degradation of the drug solution present in a drug solution container.
Also, the plastic forming the drug solution plastic container mentioned above has an oxygen gas transmission rate of not less than 200 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm at a temperature of 25 ° C and 60% RH after steam sterilization or hot water sterilization, and exhibits extremely high oxygen gas transmission compared to the circumstance that Oxygen gas transmission rate is in steady state. In addition, normally the oxygen gas transmission rate of the plastic after steam sterilization or hot water sterilization does not rapidly return to the state prior to steam sterilization or hot water sterilization. Thus, with the method of manufacturing the drug solution container package according to this invention, in which the drug solution container subjected to steam sterilization or hot water sterilization is placed and sealed together with the oxygen trap. in the outer sachet having the oxygen barrier property before the plastic oxygen gas transmission rate drops significantly, oxygen remaining within the above mentioned drug solution container (for example, oxygen remaining in the empty space of the drug solution container and dissolved oxygen in the drug solution) may be removed from inside the drug solution container .
Thus, with the above-mentioned drug solution container package and the method of manufacture thereof, it is possible to greatly prevent oxidative degradation of the drug solution existing in a drug solution container. Moreover, even when a small amount of microbes are mixed in a drug solution by mistake, it is possible to greatly prevent the proliferation of microbes.
Brief Description of the Figures
FIG. 1 is a schematic cross-sectional view of an embodiment of a plastic forming a drug solution plastic container;
FIG. 2 is a schematic cross-sectional view of another embodiment of a plastic forming a drug solution plastic container;
FIG. 3 is a schematic cross-sectional view of yet another embodiment of a plastic forming a drug solution plastic container;
FIG. 4 is a front view of one embodiment of a drug solution bag;
FIG. 5 is a graph of a time variation of an oxygen gas transmission rate of a multilayer film obtained in Example 1;
FIG. 6 is a graph of time variations of dissolved oxygen concentrations in drug solution container packages obtained in the Examples and Comparative Examples;
FIG. 7 is a graph of time variations of dissolved oxygen concentrations in drug solution containers (drug solution bags) obtained in the Examples and Comparative Examples; and FIG. 8 is a graph of a time variation of an oxygen gas transmission rate of the multilayer film obtained in Example 1 as it is placed in an outer sachet.
Description of Numbers sealing layer intermediate layer protective layer drug solution plastic container
Modes of Carrying Out the Invention
A drug solution container package according to this invention includes: a plastic drug solution container in which a drug solution is placed and sealed and which is steam sterilized or hot water sterilized; an oxygen trap; and an outer sachet for placing and sealing the above mentioned drug solution plastic container and the above mentioned oxygen trap.
In the drug solution container package according to this invention, the drug solution plastic container is comprised of a plastic with an oxygen gas transmission rate of not less than 200 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm at a temperature of 25 ° C and a humidity of 60% RH over a period of twelve hours after steam sterilization or hot water sterilization, and with a non-oxygen gas transmission rate greater than 100 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm at a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate is stable.
Particularly within the limits mentioned above, the oxygen gas transmission rate of the above plastic at a temperature of 25 ° C and a humidity of 60% RH within a time period of twelve hours after steam sterilization or sterilization. the hot water is preferably not less than 500 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm, more preferably not less than 700 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm, and even more preferably is from 700 to 1000 cm<sup>3</sup>/ m<sup>2</sup> -2 4h -atm.
In the plastic mentioned above, when the rate of oxygen gas transmission at a temperature of 25 ° C and 60% RH humidity within a period of twelve hours after steam sterilization or hot water sterilization decreases to below the limits mentioned above, the effect of oxygen removal in the empty space of the drug solution plastic container, oxygen dissolved in the drug solution, etc. of the drug solution container to the outside is reduced after steam sterilization or hot water sterilization in the drug solution plastic container, which reduces the effect of preventing and preventing oxidative degradation of a drug solution . However, although the upper limit of the oxygen gas transmission rate after steam sterilization or hot water sterilization is not limited in particular, the upper limit is approximately 1000 cm.<sup>3</sup>/ m<sup>2</sup>-24h-atm in terms of the properties of a plastic used in a drug solution plastic container.
Particularly, within the limits mentioned above, the oxygen gas transmission rate of the aforementioned plastic at a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate is in the stable state is not stable. is preferably greater than 70 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm, more preferably not exceeding 30 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm, and even more preferably 0.5 to 10 cm<sup>3</sup>/ m<sup>2</sup>-24am-atm.
If the oxygen gas transmission rate of the above plastic at a temperature of 25 ° C and a humidity of 60% RH when the oxygen gas transmission rate is in a steady state exceeds the above limits, Oxygen transmission to the drug solution container cannot be prevented when the above-mentioned drug solution container is left standing after the outer sachet of the drug solution container package is opened, for example, and this causes oxidative degradation of a drug solution in the drug solution container. On the other hand, although the lower limit of the oxygen gas transmission rate when the oxygen gas transmission rate is in the stable state preferably corresponds to zero, the lower limit is preferably approximately 0.5 cm.<sup>3</sup>/ m<sup>2</sup>-24h-atm in terms of the properties of the plastic used in the drug solution plastic container. The lower limit of the oxygen gas transmission rate may also be approximately 1 cm.<sup>3</sup>/ m<sup>2</sup>-24h-atm or about 5 cm<sup>3</sup>/ m<sup>2</sup>-24am-atm.
As mentioned above, the oxygen gas transmission rate of plastic is the oxygen gas transmission rate (O<sub>2</sub>GTR) measured according to Method B (Equal Pressure Method) defined in JIS K 712 6-1987 Testing Method for Gas Transmission Rate through Plastic Film and Sheeting. Examples of measurement equipment used to measure oxygen gas transmission rate include a product under the trademark OX-TRAN (Trademark) manufactured by MOCON, Inc., and a product under the trademark OPT-5000 manufactured by Lyssy AG.
The process conditions for steam sterilization or hot water sterilization carried out in the drug solution plastic container are not limited in particular and may be defined as suitable according to the general process conditions for sterilization of containers containing a solution. and specifically, for example, according to a type and amount of an existing drug solution, the quality of a material and the thickness of a container-forming plastic, and other conditions, as well as the consideration that sterilization of the drug solution adapts to predetermined conditions.
In general, steam sterilization is performed in an atmosphere with a temperature of 100 to 121 ° C and a saturated steam state for a heating time of 10 to 60 minutes. Although the pressurization condition during steam sterilization is not in particular limited, steam sterilization is preferably performed in an atmospheric pressure or in a pressurized atmosphere with a barometric pressure of not more than 4000 hPa, and more preferably in a pressurized atmosphere with a barometric pressure. from 2000 to 3500 hPa.
On the other hand, hot water sterilization may be carried out under conditions in accordance with conventional conditions or steam sterilization conditions by, for example, injecting or spraying hot water at a temperature of about 100 to 120 ° C. for 10 to 60 minutes at atmospheric pressure or pressurized atmosphere.
Steam sterilization or hot water sterilization is preferably performed in an inert gas atmosphere. In this case, the empty space of the drug solution container prior to being placed and sealed in the outer sachet may be replaced to some extent by the inert gas mentioned above during steam sterilization or hot water sterilization, and the amount of oxygen remaining. in the drug solution container before being placed and sealed in the outer sachet can be decreased It is possible to reduce one of oxygen chemical agent needed for oxygen in the pre-setting. amount of the drug removal then in the solution container process sachet and seal the outer container as well as the deoxygenation, and for the prevention and prevention of drug degradation solution of the necessary time the oxidative effects of a drug solution may be further improved.
Although the inert gas mentioned above is not limited in particular, it is preferably a gas, such as nitrogen, argon, etc., that does not easily cause (or prevent) oxidation and other alterations of a drug solution.
In the plastic forming the drug solution plastic container, the oxygen gas transmission rate after steam sterilization or hot water sterilization and the steady state oxygen gas transmission rate can be set to values respectively. suitable by changing the type, thickness, etc. mentioned plastic, or by altering the thickness, arrangement of a layer, etc. in which case the plastic mentioned above is a multilayer film.
Regarding the oxygen gas transmission rate of the plastic forming the drug solution plastic container, to provide a significant difference between an oxygen gas transmission rate value after steam sterilization or hot water sterilization and For a steady state oxygen gas transmission rate value, it is preferable to use a polyol based plastic such as the plastic forming the drug solution container, for example.
Ethylene vinyl alcohol copolymers may be given as examples of polyol-based plastics, although polyol-based plastics are not limited thereto.
In particular, an ethylene vinyl alcohol copolymer with an ethylene content of 10 to 45 mole% may be indicated as a preferred example.
When the ethylene content of the ethylene vinyl alcohol copolymer falls below 10 mole%, it may not be possible, for example, to ensure adequate water resistance to withstand steam sterilization or hot water sterilization. . Also, it may not be possible to return to the original value of the increased oxygen gas transmission rate by steam sterilization or hot water sterilization even after a plastic temperature has decreased.
On the other hand, when the ethylene content of the ethylene vinyl alcohol copolymer exceeds 45 mole%, bleaching due to steam sterilization or hot water sterilization occurs, and the transparency of the container decreases significantly. Likewise, the transmission rate of exceeding the steady state oxygen gas limits may be mentioned above under conditions with a temperature of 25 ° C and a humidity of 60% RH and, consequently, non-drug transmission to be possible. the container prevent solution solution after the drug is open sachet drug.
oxygen content when, for example, mentioned above is allowed to stand outside the solution container. Particularly, within the limits mentioned above, the ethylene mentioned above is preferably 25 to 35 mole%.
For purposes of improving the heat resistance of the drug solution container, a polyamide-based resin (such as nylon-6, etc.) or a phosphorus-based antioxidant [e.g. tris (2.4 -dit-butylphenyl) phosphate], for example, in the polyol-based plastic mentioned above, if necessary. A blend amount of one of these polyamide-based resins or one of these phosphorus-based antioxidants can be defined within limits within which a drug solution in the drug solution container is not affected.
From the standpoint of maintaining the basic properties as a drug solution container, the plastic forming the drug solution plastic container is preferably a multilayer structure plastic film having a polyol based plastic as an intermediate layer, a sealing layer (innermost layer) consisting of a polyolefin-based plastic on an inner surface side of the drug solution container relative to the intermediate layer, and a protective layer (outermost layer) on an outer surface side of the drug container. drug solution relative to the intermediate layer.
When, for example, the peripheral parts of the plastic film are welded to form an infusion bag, etc., the above-mentioned sealing layer (innermost layer) forms welded surfaces and becomes an inner surface of a solution container. of drug to be a surface that is in direct contact with the drug solution. The plastic forming the sealing layer mentioned above (innermost layer) is thus necessary, for example, to be heat sealed and security reinforced with respect to the drug solution.
Polyolefin-based plastics may be given as specific examples of the plastic to form the aforementioned sealing layer (innermost layer).
Examples of polyolefin-based plastics include polyethylene (ethylene homopolymer), ethylene-α-olefin copolymers, polypropylene (propylene homopolymer), random propylene-α-olefin copolymers and propylene-α-olefin block copolymers. Examples of α-olefin of the ethylene-α-olefin copolymers mentioned above include propylene, 1-butene, 1-pentene, 1-hexene, 4-methyl-1-pentene and other three to six-carbon α-olefins, and examples α-olefin of the propylene-α-olefin random copolymers and propylene-α-olefin block copolymers mentioned above include ethylene and 1-butene, 1-pentene, 1-hexene, 4-methyl-1-pentene and others α-olefins with four to six carbons.
Among the examples provided above, polyethylene, polypropylene and mixed resins thereof may be indicated as being preferred as the polyolefin-based plastic used in the sealing layer.
In the case, for example, of preparing a bag-type drug solution container with a plurality of container chambers (the so-called multiple chamber bag) which are divided into parts by barriers with an easy peel property (sealing parts which easily detached), The sealing layer is preferably made of a plastic made from a mixed resin of polyethylene and polypropylene to facilitate the formation of easily peelable sealing portions.
The above protective layer (outermost layer) is a layer that forms an outer surface of the drug solution plastic container. 0 plastic forming the above-mentioned protective layer (outermost layer) is thus selected as suitable, for example, from the point of view of preventing the direct influence of moisture on the intermediate layer consisting of the polyol-based plastic mentioned above, and from the view of the maintainability of a predetermined resistance according to a shape, an application, etc. of the drug solution container during steam sterilization or hot water sterilization.
The above-mentioned protective layer (outermost layer) or all of the above-mentioned multilayer film layers which are disposed on the outer surface side of the drug solution plastic container with respect to the above-mentioned intermediate layer are necessary to prevent intermediate layer, made up of the polyol-based plastic mentioned above, is directly affected by moisture and still has some water vapor transmission rate, in order to provide the actions and effects of the present invention. Although the water vapor transmission rate of the protective layer (or all layers of the above mentioned multilayer film which are arranged on the outer surface side of the drug solution plastic container relative to the above mentioned intermediate layer) is not In particular, the rate of transmission of water vapor at a temperature of 25 ° C and a humidity of 90% RH is preferably 1 g / m 2.<sup>2</sup>-24h, more preferably from 3 to 30 g / m<sup>2</sup>-24h, and even more preferably from 3 to 10 g / m<sup>2</sup>-24h.
The water vapor transmission rate mentioned above is measured according to Method A (Humidity sensor method) defined in JIS K 712 9-1992, Testing Methods for water vapor transmission rate (instrument method) of Plastic Film and Sheeting.
Specific examples of plastic to form the above-mentioned protective layer (outermost layer) include polyolefin-based, polyamide-based and polyester-based plastics. As examples of the polyolefin-based plastic mentioned above, the same plastics provided as examples above may be indicated. Nylons, such as nylon-6, nylon-6, 6, and nylon-6, 10 may be given as examples of the polyamide-based plastic mentioned above. Polyethylene terephthalate, butylene polyterephthalate, etc. may be indicated as examples of the polyester-based plastic mentioned above.
In the case where the plastic forming the drug solution plastic container is a multilayer film, the multilayer film having the three layer structure having, as mentioned above, the sealing layer consisting of the plastic based polyolefin as the innermost layer making up the inner surface side of the drug solution plastic container, the protective layer as the outermost layer making up the outer surface side of the drug solution plastic container, and the intermediate layer consisting of the polyol-based plastic between the aforementioned sealing layer and the aforementioned protective layer may be indicated as a specific embodiment.
Preferably, the aforementioned multilayer film additionally has a low water absorption layer consisting of a low water absorption plastic on the inner surface side (sealing layer side) of the drug solution plastic container relative to the intermediate layer mentioned above.
In this case, it is possible to create the intermediate layer comprised of the above mentioned polyol-based plastic less likely to be affected by the water content in the drug solution.
Examples of the low water absorption plastic mentioned above include cycloolefin polymers, etc.
A cyclolefin polymer has an extremely low water absorption rate, specifically no greater than 0.01%, and is thus favorable for reducing the effects of moisture on the intermediate layer made of polyol-based plastic.
The water absorption rate mentioned above is measured according to Method B (water absorption after immersion in boiling water) defined in JIS K 72O9_2ooo Plastics
Determination of water absorption.
Specific examples of cycloolefin polymers include such cycloolefin polymers as ethylene copolymers (and hydrogenated substances thereof) and dicyclopentadiene-based compounds, ethylene copolymers (and hydrogenated substances thereof) and norbornene-based compounds, ring polymers (and hydrogenated substances thereof) of cyclopentadiene-based compounds, and open ring copolymers consisting of two or more types of cyclopentadiene compounds (and hydrogenated substances thereof).
The aforementioned multilayer film may additionally include a layer comprised of an elastomer-containing plastic for the purpose of adding malleability, transparency and impact resistance to the drug solution plastic container.
Examples of the aforementioned elastomer include polyolefin-based elastomers, such as polyethylene-based elastomers and polypropylene-based elastomers, and others, and styrene-based elastomers, such as styrene-ethylene / butylene-styrene block copolymers (SEBS), copolymers in (SBS), copolymers in (SIS), modified SEBS block styrene-butadiene styrene block copolymer block copolymers Among these in styrene-isoprene-styrene by maleic acid, etc., styrene-ethylene / propylene-styrene copolymers styrene-ethylene / butylene block styrene-ethylene / propylene block can be (SEPS) (SEB) (SEP) the
listed as examples Although not formed for an extrusion form, such as insufflation, plastic that drug. To preferable elastomers based.
limited to the same polyethylene, film by T-mold method, etc. can be indicated as a plastics method method of example forming the solution plastic container forming the above mentioned drug solution container using a plastic film so it is possible to form a drug solution plastic container with a excellent flexibility and suppleness.
FIGs. 1-3 are schematic cross-sectional views of preferred embodiments of the multilayer film layer arrangements in cases where the plastic forming the drug solution plastic container is the multilayer film. Although this invention is not limited thereto, preferred embodiments include, for example:
(I) a multilayer film having a seven-layer structure having, with an order of an innermost layer constituting an inner surface side I of a drug solution plastic container to an outermost layer constituting a outer surface side 0 of a drug solution plastic container, a sealing layer 1 made of a mixed polyethylene and polypropylene resin, a layer 2 made of polyethylene, a low water absorption layer 3 made of a cyclolefin polymer, an intermediate layer 4 made of an ethylene vinyl alcohol copolymer, and a protective layer 5 made of polyethylene, further having adherent layers 6 and 7 in each is comprised of an adherent resin (e.g., an adherent polyolefin, etc.) and disposed between the low water absorption layer and the intermediate layer between the intermediate layer and the protective layer.
5, respectively (see (II) is a multilayer film having a six-layer structure having, with an innermost layer order constituting an inner surface side
1 from the drug solution plastic container to the outermost layer forming an outer surface side 0 of the drug solution plastic container, a sealing layer 1 consisting of a mixed polyethylene and polypropylene resin, a layer 2 formed of polyethylene, an intermediate layer 4 consisting of an ethylene vinyl alcohol copolymer, and a protective layer each comprising an adherent resin (e.g. an adherent polyolefin, etc.) and disposed between the polyethylene layer 2 and the intermediate layer 4 and between the intermediate layer 4 and the protective layer 5, respectively (see FIG. 2); and (III) a multilayer film having a four layer structure having, with an innermost layer order constituting an inner surface side.
1 from the drug solution plastic container to the outermost layer forming an outer surface side 0 of the drug solution plastic container, a sealing layer 1 'composed of polyethylene, a low water absorption layer consisting of a cycloolefin polymer, an intermediate layer 4 made of an ethylene vinyl alcohol copolymer, and a protective layer 5 made of polyethylene (see FIG. 3).
With the multilayer film described above in (III), adherence of the low water absorption layer 3 to the intermediate layer 4 and the intermediate layer 4 to the protective layer 5 can be achieved by applying an adhesive agent between the respective layers. Alternatively, the adhesive layers consisting of an adhesive resin may be interposed in the same manner as in the multilayer films described in (I) and (II) above. However, in the above layered films, the adhesion of the multiple intermediate layer 4 described in low absorption layer and the intermediate layer achieved by simply applying a protective 5 may be adhesive without placing the adhesive layers (6, 7 and
8) between the respective layers.
In the multilayer films described above, respective is not limited so defined that, as a drug solution, the oxygen rate after steam sterilization in hot water and the rate of transmission limits particular thickness container transmission of the layers and It may be plastic gas or the oxygen gas sterilization provided above.
in one of in steady state meet the
After forming the drug plastic container, for example, as a malleable solution bag, preferably, the thickness of the above mentioned drug layer solution is set to 3 to 20 pm and the thickness of the entire multilayer film is set to approximately 180 to 300 pm.
The shape of the drug solution plastic container is not limited in particular and may, for example, be a bag-type drug solution container with excellent flexibility and malleability, such as an infusion bag as mentioned above (see FIG. 4), or may be a drug solution container, such as an infusion bottle, which has a strength to independently maintain the shape of the container without losing flexibility and malleability. The above-mentioned bag-type drug solution container, such as an infusion bag, may be a single chamber drug solution bag or a so-called multi-chamber bag with a variety of container chambers divided into sealing portions that may be be easily unglued.
The methods for forming these infusion bags, infusion bottles, etc. They are not limited in particular, and various methods such as lamination, coextrusion, etc. may be selected and used as appropriate according to a form of the drug solution container.
In the drug solution container package according to this invention, a drug solution in the drug solution plastic container is not limited in particular, and various drug solutions may be given as examples. In particular, since in the plastic drug solution container described above, oxygen from outside is prevented in a normal environment in which the drug solution container is used, and since oxygen remaining in the void and dissolved oxygen in the drug solution are removed over time due to the drug solution container being placed and sealed after steam sterilization or hot water sterilization together. with the oxygen trap in the outer sachet having the oxygen barrier property, an infusion, especially an infusion containing an easily oxidizable substance such as L-cysteine,
L-Tryptophan, Fat, Vitamin A, Vitamin BI or Vitamin
C, is favorable as a drug solution placed in the plastic solution container. In the solution container package of this invention, the outer oxygen-barrier sachet has a rate preferably, more preferably, a temperature of 25 ° C to be a drug.
drug according to oxygen gas transmission property, cm<sup>3</sup>/ m<sup>2</sup>-24h-atm and at 0.1 cm<sup>3</sup>/ m<sup>2</sup> 24h-atm not
0.5 higher than no higher and with a humidity of 60% RH.
an
When the oxygen gas transmission rate of the outer sachet exceeds the above mentioned limits, it becomes difficult to obtain the effect of the subsequent removal of oxygen remaining in the empty space of the drug solution plastic container and of the dissolved oxygen in the solution. drug.
Also, the outer sachet preferably has a water vapor transmission property to some extent. In this case, moisture within the outer sachet can be released to the outside, and it is possible to make the oxygen gas transmission rate of the drug solution plastic container easily reach the stable state.
Preferred limits for the outer sachet water vapor transmission rate are about 0.5 to 30 g / m<sup>2</sup> -24h, although this depends on the combination with the oxygen barrier property.
The material for forming the outer sachet is not limited in particular, and examples thereof include:
a multilayer film having a melt adhesion layer forming an inner surface of the outer sachet and consisting of a heat-sealed plastic (e.g. a polyolefin such as polyethylene, polypropylene, etc.) and a sheet of aluminum laminated to an outer surface side of the outer sachet relative to the melt adhesion layer; and a film comprising a deposited vapor film with the above mentioned melt adhesion layer and a deposited vapor film of an inorganic material (such as aluminum, etc.) or an inorganic oxide (such as alumina, etc.) formed. on an outer surface side of the outer sachet relative to the melt adhesion layer.
Examples of inorganic oxide in the inorganic oxide deposited vapor film include alumina (aluminum oxide), silica (silicon oxide), magnesium oxide and titanium oxide. Among these, alumina may be indicated as a preferable example from the point of view of transparency of the deposited vapor film.
As a material for forming the outer sachet having some water vapor transmission property, it may be indicated as an example a multilayer film in which a plastic layer consisting of polyvinyl alcohol, vinylidene polychloride or the like and having a suitable oxygen barrier property and water vapor transmission property is laminated to the outer surface of a melt adhesion layer.
An outer sachet material of the above-mentioned examples may additionally have a light-blocking impression utilizing an ink containing a dye or an ultraviolet absorber on the outer surface side of the outer sachet, or may have a protective film consisting of polyester or polyolefin, etc. on the outer surface side of the outer sachet.
In the drug solution container package according to this invention, the oxygen trap is not limited in particular, various oxygen chemical agents may be given as examples. Specifically, oxygen chemical agents containing an iron compound, such as iron hydroxide, iron oxide, iron carbide, etc. may be given as examples. as the effective component, and oxygen chemical agents using low molecular weight phenol and activated carbon. Examples of commercially available oxygen chemical agents include Ageless (trademark) manufactured by Mitsubishi Gas Chemical Company, Inc., Modulan (trademark) manufactured by Nippon Kayaku Company, Inc., Secule (trade name) manufactured by Nippon Soda Co. , Ltd. and Tamotsu (registered trademark) made by Oji Kako, Co., Ltd.
The oxygen trap may, for example, be placed together with the steam sterilized or hot-water sterilized drug solution container in the above-mentioned outer sachet in a state in which the oxygen trap is introduced into a plastic film bag. with a high oxygen gas transmission rate (such as a polyolefin film).
By drug solution container packaging and the method of manufacture thereof according to this invention, a drug solution which even contains an easily oxidizable substance, for example, can be stored with stability and without oxidative degradation for a long period. of time. In addition, oxidative degradation of a drug solution can be prevented during use of a drug solution bag. Examples
Although this invention is described below based on the examples and comparative examples, this invention is not limited by the following examples.
<Preparation of Solution Solution Plastic Container
Drug>
The respective components constituting the plastics (multilayer films) for forming drug solution plastic containers are presented below.
PE (1): ethylene-1-butene copolymer [density: 0.940 g / cm<sup>3</sup>, water vapor transmission rate: 7 g / m<sup>2</sup>-24h (25 ° C, 90% RH, 20 pm), Trade Name: Ultzex (Trade Mark) 4020B, manufactured by Prime Polymer Co., Ltd.]
PE (2): 45% by weight mixture of ethylene-1-butene copolymer [density: 0.920 g / cm<sup>3</sup>, Trade Name: Ultzex (Trade Mark) 2010, Manufactured by Prime Polymer Co., Ltd.], Ethylene-1-Butene Copolymer g / cm<sup>3</sup>, trade name: Tafmer
50% by weight of [density: 0.885 (trademark)
A0585X, manufactured by Prime Polymer Co., Ltd.], and 5 wt% polyethylene homopolymer [density: 0.965 g / cm<sup>3</sup>, trade name: Hi-zex (registered trademark)
65150B, manufactured by Prime Polymer
EVOH (l): ethylene content: 27% commercial: Eval (registered trademark) by Kuraray Co., Ltd.
EVOH (2): ethylene content: 44% commercial: Eval (registered trademark)
Co., Ltd.] in moles, name
L101, made of moles, name
E105, manufactured by Kuraray Co., Ltd.
COP: norbornene-based open-ring polymer hydrogenated substance [water absorption percentage: less than 0.01%, trade name: Zeonor (trade mark) 1020R, manufactured by Zeon Corporation]
PP: polypropylene (density: 0.900 g / cm<sup>3</sup>, trade name: B355, manufactured by Prime Polymer Co., Ltd.)
ΝΥ: nylon-6 [trade name: Amilan (trademark) CM1017, made by Toray Industries Inc.]
PE-PP: mixture of 85 wt% PE (1) mentioned above and 15 wt% polypropylene homopolymer (density: 0.910 g / cm<sup>3</sup>, trade name: J103WA, manufactured by Prime Polymer Co., Ltd.)
Adherent PE: Unsaturated carboxylic acid modified polyethylene [density: 0.905 g / cm<sup>3</sup>, water vapor transmission rate: 10 g / m<sup>2</sup>-24h (25 ° C, 90% RH, 20 pm), adherent polyolefin with the trade name: Admer (trademark), manufactured by Prime Polymer Co., Ltd.]
PBT: polyethylene terephthalate [water vapor transmission rate: 23 g / m<sup>2</sup>-24h (25 ° C, 90% RH, 10 pm), manufactured by Mitsubishi Engineering-Plastics Corporation]
Example 1
The respective layers illustrated in Table 1 were coextruded molded to be laminated in the order indicated in Table 1 to obtain a multilayer film to form a drug solution bag (drug solution plastic container) 10 shown in FIG. 4. This multilayer film is a film with the seven layer structure illustrated in FIG. 1. A water vapor transmission rate of a laminate consisting of a protective layer 5 and an adherent layer 7 of this multilayer film corresponded to 4.1 g / m<sup>2</sup>-24h (25 ° C, 90% RH).
The two multilayer films described above were then overlapped, and the peripheral portions 11 were heat-sealed by a standard method for preparing the drug solution bag 10 illustrated in FIG. 4. A door-type input member, molded using the PE (1) mentioned above, was used as an input member 12.
Example 2
The respective layers illustrated in Table 1 have been coextruded molded so that they are laminated in the order given in Table 1 to obtain a multilayer film to form a drug solution bag 10. This multilayer film is a film with the six-layer structure illustrated in FIG. 2.
Next, except for using two of these multilayer films, the drug solution bag 10 illustrated in FIG. 4, was prepared in the same manner as Example 1.
Comparative Example 1
The respective layers illustrated in Table 1 were coextruded molded so that they were laminated in the order given in Table 1 to obtain a multilayer film to form a drug solution bag 10. This multilayer film is a single layer film. similar seven-layer structure as illustrated in FIG. 1.
Next, except for using two of these multilayer films, the drug solution bag 10 illustrated in FIG. 4, was prepared in the same manner as Example 1.
Comparative Example 2
The respective layers illustrated in Table 1 were coextruded molded so that they were laminated in the order given in Table 1 to obtain a multilayer film to form a drug solution bag 10. This multilayer film is a single layer film. Five-layer structure that does not have a cling layer.
Next, except for using two of these multilayer films, the drug solution bag 10 illustrated in FIG. 4, was prepared in the same manner as Example 1.
Layer of drug solution bag
<td>10 and the rates of</td><td>transmit</td><td>are gas</td><td>of oxygen</td><td>of the film</td>
<td colspan="2">multilayer that</td><td colspan="2">form solution bag</td><td>of drug</td>
<td colspan="2">10 are illustrated for</td><td>each one</td><td>of the Examples</td><td>1 and 2 and</td>
<td>Comparat Examples</td><td>ivo 1 and</td><td colspan="2">2 in Table 1.</td><td></td>
<td></td><td></td><td>Table 1</td><td></td><td></td>
<td></td><td>Example 1</td><td>Example 2</td><td>Comparative Example 1</td><td>Comparative Example 2</td>
<td colspan="2"><Layer Layout</td><td></td><td></td><td></td>
<td>Layer Film Multiples> (Outside surface side 0)</td><td></td><td></td><td></td><td></td>
<td>Protective layer</td><td>PE (1) (20 pm)</td><td>PE (1) (20 pm)</td><td>PE (1) (20 pm)</td><td>PE (1) (20 pm)</td>
<td></td><td>PE</td><td>PE</td><td>PE</td><td></td>
<td>Cling layer</td><td>sticky (20 pm)</td><td>sticky (20 pm)</td><td>sticky (20 pm)</td><td> -</td>
<td>Middle layer</td><td>EVOH (1) (5 pm)</td><td>EVOH (2) (5 pm)</td><td> -</td><td> -</td>
<td>Another layer</td><td> -</td><td> -</td><td>NY (5 pm )</td><td>PE (2) (100 pm)</td>
<td>Cling layer</td><td>Adherent PE (20 pm)</td><td>Member (20 pm)</td><td>Adherent PE (20 pm)</td><td> -</td>
<td>Low water absorption layer</td><td>COP</td><td> -</td><td>COP (10 pm)</td><td> -</td>
<td>Another layer</td><td> -</td><td> -</td><td> -</td><td>PP (10 pm)</td>
<td>Polyethylene layer</td><td>PE (2) (145 pm)</td><td>PE (2) (155 pm)</td><td>PE (2) (145 pm)</td><td>PE (2) (100 pm)</td>
<td>Sealing Layer (Side of</td><td>PE-PP</td><td>PE-PP</td><td>PE-PP</td><td>PE-PP</td>
<td>inner surface I)</td><td>(30 pm)</td><td>(30 pm)</td><td>(30 pm)</td><td>(30 pm)</td>
<Total thickness of multilayer film>
<td></td><td>250 pm</td><td>250 pm</td><td>250 pm</td><td>2 60 pm</td>
<td><Baud rate</td><td>of gas</td><td></td><td></td><td></td>
<td>oxygen> steady state</td><td> 5</td><td> 20</td><td> 270</td><td> 900</td>
<td>Six hours after sterilization</td><td> 800</td><td> 800</td><td> -</td><td> -</td>
<td>* Numeric values</td><td>cos between</td><td>parentheses</td><td>in column</td><td>Disposition of</td>
<td>Film Layers</td><td>Layer</td><td>Multiple</td><td colspan="2">match the thickness</td>
<td>Example 1</td><td>Example 2</td><td>Comparative Example 1</td><td>Comparative Example 2</td>
<td colspan="2">of the respective layers. * The transmission rate unit of cm<sup>3</sup>/ m<sup>2</sup>-24am-atm.</td><td>oxygen gas</td><td>stands for</td>
CT Plastic Evaluation Test for Forming Drug Solution Plastic Container>
The multilayer film obtained in Example 1 was subjected to 30 minutes of high pressure steam sterilization in a nitrogen atmosphere in a saturated vapor state (temperature: 110 ° C, pressure: 2700 hPa) and then subjected to removal. of water from a hot air multilayer film surface of approximately 40 ° C. After steam sterilization, the multilayer film was allowed to stand for three weeks in an atmosphere with a temperature of 25 ° C and a humidity of 60% RH to observe a change in oxygen gas transmission rate over time. (temperature: 25 ° C, humidity: 60% RH). The product called OX-TRAN (Trademark) manufactured by MOCON, Inc. was used to measure oxygen gas transmission rate.
FIG. 5 is a graph of results of measuring the change over time of the oxygen gas transmission rate. As illustrated in FIG. 5, after steam sterilization described above, it took approximately three days for the oxygen gas transmission rate (temperature: 25 ° C, humidity: 60% RH) of the multilayer film to reach stable state. <Preparation of Drug Solution Container Packages>
Each of the drug solution bags 10 prepared in Examples 1 and 2 and Comparative Examples 1 and 2 were filled with 300 mL of distilled water for injection and then sealed. A void volume was set to approximately 30 mL, and nitrogen replacement (approximately 50%) was performed so that the void nitrogen concentration was 10%.
The drug solution bag 10 was then autoclaved and subjected to high pressure steam sterilization by heating for 30 minutes in a nitrogen atmosphere in a saturated vapor state (temperature: 110 ° C, pressure: 2700 hPa). The oxygen concentration in this nitrogen atmosphere was adjusted to not exceed 2%.
Following high pressure steam sterilization, water was removed by blowing hot air of approximately 40 ° C to remove moisture from the outer surface of each drug solution bag 10 and then each drug solution bag 10. was placed and sealed, along with an oxygen trap [trade name: Ageless (trademark) manufactured by Mitsubishi Gas Chemical Co.], in an outer sachet to obtain a drug solution container package.
The outer sachet mentioned above is a sachet consisting of a multilayer film having a three-layer structure, in which an inner surface layer is made of polyethylene, an intermediate layer is a polyvinyl alcohol outer surface layer, and one is polypropylene, and its oxygen gas transmission rate at a temperature of 25 ° C and a humidity of 60% RH was not more than 0,1 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm and the water vapor transmission rate thereof at a temperature of 25 ° C and a humidity of 90% RH corresponded to 0.5 g / m<sup>2</sup>-24h. The volume of the inner space of the outer sachet was set to approximately 300 to 500 ml and the oxygen concentration inside the outer sachet was adjusted to not exceed 2% nitrogen replacement.
The time taken to place and seal the drug solution bag in the outer sachet after high pressure steam sterilization was about one hour.
The Drug Solution Container Package Evaluation Test 1>
Each of the drug solution container packages obtained in Examples 1 and 2 and Comparative Examples 1 and 2 described above were allowed to stand in an environment of 25 ° C and 60% RH and all days oxygen concentration in a liquid content was measured using a non-destructive oxygen concentration meter (trade name:
Fibox 3 manufactured by PreSens GmbH).
As a consequence, it has been verified as illustrated in FIG. 6 that for all drug solution container packages of Examples 1 and 2 and
Comparative Examples 1 and 2, the concentration of oxygen in the liquid content may be reduced to no more than 1 ppm over approximately seven days from placement and sealing in the outer sachet.
Test Solution 2 for Drug Solution Container Packs>
Each of the drug solution container packages used in the Assessment Test 1 described above was further left to stand for seven days from the preparation of the drug solution container package to approximate the oxygen concentration value of the liquid content to be 0 ppm. Then, in an environment with a temperature of 25 ° C and a humidity of 60% RH, the drug solution bag 10 was removed from the outer sachet, and while the bag was in an environment with a temperature of 25 ° C and a At 60% RH in a suspended state for an infusion bag, oxygen concentration in the liquid content was measured using the non-destructive oxygen concentration meter (the Fibox 3 mentioned above) at each predetermined time period.
As a consequence, in the drug solution bags of Examples 1 and 2, oxygen entering the liquid content can be prevented as much as possible as shown in FIG. 7, even after it has been removed from the outer sachet. On the other hand, there was a significant oxygen intake in the drug solution bags of Comparative Example 1 and Comparative Example 2.
The Drug Solution Container Packing Evaluation Test 3>
Each of the drug solution container packages obtained in Example 1 described above (samples other than those used in Assessment Tests 1 and 2) were allowed to stand for several days in an environment with a temperature of 25 ° C and a humidity of 60 ° C. % RH, and for each of the drug solution container packages thus prepared, the drug solution bag was removed, and after cutting the film and removing moisture, The oxygen gas transmission rate of the film was measured using the product called OX-TRAN (Trademark) manufactured by MOCON, Inc. The results are illustrated in FIG. 8
As illustrated in FIG. 8, when wrapped in the outer sachet, the multilayer film exhibited a high oxygen gas transmission rate (temperature: 25 ° C, humidity: 60% RH) for approximately three to four days after steam sterilization. high pressure. Also, it has been found that after steam sterilization, it takes approximately ten days for the oxygen gas transmission rate to reach steady state. Oxygen in the drug solution bag 10 can thus be suitably absorbed by the oxygen trap before the oxygen gas transmission rate returns to steady state after steam sterilization. <Preparation of Drug Solution Plastic Containers>
Example 3
By using the plastics indicated above as examples, the respective layers illustrated in Table 2 were coextruded to be laminated in the order shown in Table 2 to obtain a multilayer film to form a drug solution bag (container of drug solution plastic) 10 illustrated in FIG. 4. This multilayer film is a film with the seven layer structure illustrated in FIG. 1. The water vapor transmission rate of a laminate consisting of a protective layer 5 and an adherent layer 7 of this multilayer film corresponded to 4.1 g / m<sup>2</sup>-24h (25 ° C, 90% RH).
The two multilayer films described above were then overlapped, and their peripheral parts 11 were heat sealed by a standard method for preparing a drug solution bag 10 illustrated in FIG. 4. A door-type input member, molded using the PE (1) mentioned above, was used as an input member 12.
Example 4
The respective layers illustrated in Table 2 were coextruded molded so that they were laminated in the order given in Table 2 to obtain a multilayer film to form a drug solution bag 10. This multilayer film is a film with the seven-layer structure illustrated in FIG. 1. The water vapor transmission rate of a laminate consisting of a protective layer 5 and an adherent layer 7 of this multilayer film corresponded to 7.0 g / m<sup>2</sup>-24h (25 ° C, 90% RH).
Next, except for using two of these multilayer films, the drug solution bag 10 illustrated in FIG. 4, was prepared in the same manner as Example 3.
Example 5
The respective layers illustrated in Table 2 were coextruded molded so that they were laminated in the order indicated in Table 2 to obtain a multilayer film to form a drug solution bag 10. This multilayer film is a film with the six-layer structure illustrated in FIG. 2. The water vapor transmission rate of the laminate, consisting of a protective layer 5 and an adherent layer 7 of this multilayer film, corresponded to 5.1 g / m<sup>2</sup>-24h (25 ° C, 90% RH).
Next, except for using two of these multilayer films, the drug solution bag 10 illustrated in FIG. 4, was prepared in the same manner as Example 3.
Example 6
The respective layers illustrated in Table 2 were coextruded molded so that they were laminated in the order given in Table 2 to obtain a multilayer film to form a drug solution bag 10. This multilayer film is a film with the seven-layer structure illustrated in FIG. 1. The water vapor transmission rate of a laminate consisting of a protective layer 5 and an adherent layer 7 of this multilayer film was 3.2 g / m<sup>2</sup>-24h (25 ° C, 90% RH).
Next, except for using two of these multilayer films, the drug solution bag 10 illustrated in FIG. 4, was prepared in the same manner as Example 3.
The layer arrangement of the drug solution bag and the oxygen gas transmission rates of the multilayer film forming the drug solution bag 10 are illustrated for each of Examples 3 to 6 in Table 2.
Table 2
<td></td><td>Example 3</td><td>Example 4</td><td>Example 5</td><td>Example 6</td>
<td colspan="2"><Layer Layout</td><td></td><td></td><td></td>
<td>Layer Film (Outside Surface Side 0)</td><td>Multiples></td><td></td><td></td><td></td>
<td>Protective layer</td><td>PE (1) (20 pm)</td><td>PBT (1) (10 pm)</td><td>PE (1) (16 pm)</td><td>PE (1) (30 pm)</td>
<td></td><td>PE</td><td>PE</td><td>PE</td><td>PE</td>
<td>Cling layer</td><td>sticky</td><td>sticky</td><td>sticky</td><td>sticky</td>
<td></td><td>(20 pm)</td><td>(20 pm)</td><td>(16 pm)</td><td>(20 pm)</td>
<td>Middle layer</td><td>EVOH (1) (15 pm)</td><td>EVOH (1) (5 pm)</td><td>EVOH (1) (4 pm)</td><td>EVOH (1) (5 pm)</td>
<td></td><td>PE</td><td>PE</td><td>PE</td><td>PE</td>
<td>Cling layer</td><td>sticky</td><td>sticky</td><td>sticky</td><td>sticky</td>
<td></td><td>(20 pm)</td><td>(20 pm)</td><td>(16 pm)</td><td>(20 pm)</td>
<td>Low layer</td><td>COP</td><td>COP</td><td></td><td>COP</td>
<td>water absorption</td><td>(10 pm)</td><td>(10 pm)</td><td></td><td>(10 pm)</td>
<td>Constituted layer</td><td>PE (2)</td><td>PE (2)</td><td>PE (2)</td><td>PE (2)</td>
<td>by polyethylene</td><td>(130 pm)</td><td>(155 pm)</td><td>(124 pm)</td><td>(175 pm)</td>
<td>Sealing layer</td><td>PE-PP (30 pm)</td><td>PE-PP (30 pm)</td><td>PE-PP (24 pm)</td><td>PE-PP (40 pm)</td>
<td>(Inner surface side I)</td><td></td><td></td><td></td><td></td>
<td><Baud rate</td><td>steam</td><td>layer water</td><td>protective</td><td>+ layer</td>
adhesive>
4,1 7,0 5, 1 3,2
<td colspan="5"><Total film thickness of</td>
<td>multiple layers></td><td>250 pm</td><td>250 pm</td><td>2 00 pm</td><td>300 pm</td>
<td><Oxygen transmission rate> steady state</td><td>of gas 1</td><td> 2</td><td> 25</td><td> 5</td>
<td>Six hours after sterilization</td><td> 500</td><td> 200</td><td> 1000</td><td> 500</td>
* Numeric values in parentheses in the Multiple Layer Film Layer Array column correspond to the thickness of the respective layers.
* Oxygen gas transmission rate unit is cm<sup>3</sup>/ m<sup>2</sup>-24am-atm.
* Unit of water vapor transmission rate corresponds to g / m<sup>2</sup> -24h.
<Preparation of Drug Solution Container Packages>
Each of the drug solution bags 10 prepared in Examples 3 to 6 was filled with 300 mL of distilled water for injection and then sealed. A void volume was set to approximately 30 mL, and nitrogen replacement (approximately 50%) was performed so that a void nitrogen concentration was 10%.
Each bag of drug solution 10 was then autoclaved and subjected to high pressure steam sterilization by heating for 30 minutes in a nitrogen atmosphere in a saturated vapor state (temperature: 110 ° C, pressure: 2700 hPa). The oxygen concentration in this nitrogen atmosphere was adjusted to not exceed 2%.
Following high pressure steam sterilization, water was removed for one minute by blowing hot air of approximately 40 ° C to remove moisture from the outer surface of each drug solution bag 10 and then each solution bag. 10 was placed and sealed, along with an oxygen trap (trade name: Ageless (trademark) made by Mitsubishi Gas Chemical Co.), in an outer sachet to obtain a drug solution container.
In each of Examples 3, 5 and 6, a sachet consisting of a multilayer film having a three-layer structure in which an inner surface layer is made of polyethylene, an intermediate layer is made of polyvinyl alcohol, a outer surface layer consists of expanded polypropylene, the oxygen gas transmission rate at a temperature of 25 ° C and a humidity of 60% RH was not more than 0.1 cm<sup>3</sup>/ m<sup>2</sup>-29 h-atm, and the water vapor transmission rate at a temperature of 25 ° C and a humidity of 90% RH corresponded to 0.5 g / m<sup>2</sup> -24h was used as the outer sachet mentioned above.
In Example 4, on the other hand, a sachet consisting of a multilayer film having a three-layer structure in which an intermediate layer is composed of an ethylene vinyl alcohol copolymer, the inner and outer layers are made of polyethylene. , the rate of transmission of oxygen gas at a temperature of 25 ° C and a humidity of 60% RH was 0.5 cm<sup>3</sup>/ m<sup>2</sup>-24h-atm, and the oxygen gas transmission rate at a temperature of 25 ° C and a humidity of 90% RH was 3 cm<sup>3</sup>/ m2 -24h-atm, was used as the outer sachet.
The interior space volume of each of the outer sachets described above was set to approximately 300 to 500 mL and the oxygen concentration within the outer sachet was adjusted to not exceed 2% nitrogen replacement.
Drug Solution Container Packaging Evaluation Tests>
By performing the same test as the Evaluation Test 1 described above on each of the drug solution container packages obtained in Examples 3 to 6 described above, it was found that in all cases the concentration of oxygen in the liquid content could be be reduced to not more than 1 ppm within approximately seven days of placing and sealing in the outer sachet.
In performing the same test as Assessment Test 2 described above, it was found that in each of Examples 3, 4 and 6 the oxygen concentration in the liquid content was less than 0.5 ppm after 96 hours (four days). from the moment it was withdrawn from the outer sachet, and the oxygen entering a liquid content was thus prevented as much as possible. However, in Example 5, the concentration of oxygen in the liquid content was found to be less than 2 ppm after 72 hours (three days) after it was removed from the outer sachet, and the oxygen inlet in a liquid content was found in the allowable limits properly.
Although in the above description the present invention is provided in the form of exemplary embodiments of the invention, these are examples only and should not be construed as limiting the invention. Modifications of this invention that are obvious to those skilled in the art are included within the scope of the Claims provided below.
Industrial Applicability
By packaging the drug solution container and the method of manufacture thereof according to this invention, it is possible to greatly prevent oxidative degradation of a drug solution existing in a drug solution container. This invention is thus favorable for medical container applications, such as drug solution containers and infusion containers, and is particularly favorable for medical container applications containing a drug solution, etc. which contain an easily oxidizable substance.
DOCUMENTS REFERRED TO IN THE DESCRIPTION
This list of documents referred to by the author of this patent application is for the reader's information only. It is not an integral part of the European patent document. Notwithstanding its careful preparation, IEP assumes no responsibility for any errors or omissions.
Patent documents referred to in the description
<td> •</td><td>JP</td><td> 63275346</td><td>THE</td><td> [0006]</td>
<td> •</td><td>JP</td><td> 11285520</td><td>THE</td><td> [0006]</td>
<td> •</td><td>JP</td><td> 10080464</td><td>THE</td><td> [0006]</td>
<td> •</td><td>EP</td><td> 1245217</td><td>A2</td><td> [0007]</td>
<td> •</td><td>EP</td><td> 1396249</td><td>A2</td><td> [0007]</td>
Contents3
24 members in 12 offices
Priority claims4
| Document | Office | Kind | Date |
|---|---|---|---|
| 2005132624 | Japan | A | |
| 2005132624 | Japan | A | |
| 2005132624 | – | – | – |
| JP20050132624 | – | – | – |
Members24
| Document | Office | Kind | |
|---|---|---|---|
| AU2006241992A1 | Australia | A1 | |
| CA2604611A1 | Canada | A1 | |
| WO2006118034A1 | World Intellectual Property Organization (WIPO) | A1 | |
| TW200716079A | Taiwan Province of China | A | |
| KR20080003423A | Republic of Korea | A | |
| EP1875889A1 | European Patent Office (EPO) | A1 | |
| CN101180026A | China | A | |
| TWI299988B | Taiwan Province of China | B | |
| JPWO2006118034A1 | Japan | A1 | |
| US2009032426A1 | United States of America | A1 | |
| JP2011212505A | Japan | A | |
| AU2006241992B2 | Australia | B2 | |
| AU2006241992B8 | Australia | B8 | |
| CN101180026B | China | B | |
| JP4939405B2 | Japan | B2 | |
| KR101231965B1 | Republic of Korea | B1 | |
| JP5167392B2 | Japan | B2 | |
| US8465819B2 | United States of America | B2 | |
| CA2604611C | Canada | C | |
| EP1875889A4 | European Patent Office (EPO) | A4 | |
| EP1875889B1 | European Patent Office (EPO) | B1 | |
| DK1875889T3 | Denmark | T3 | |
| PT1875889EThis record | Portugal | E | |
| ES2529741T3 | Spain | T3 |
Numbers
- Publication
- 1875889
- Publication, DOCDB
- 1875889
- Publication, EPODOC
- PT1875889E
- Application
- 67454389
- Application, DOCDB
- 06745438
- Application, EPODOC
- PT20060745438T
Titles2
- English
- HOUSING BODY FOR MEDICAL LIQUID CONTAINER AND PROCESS FOR PRODUCING THE SAME
- Portuguese
- INVÓLUCRO PARA RECIPIENTE DE LÍQUIDO MÉDICO E RESPETIVO PROCESSO DE PRODUÇÃO
Classification
- CPC, 7
- B32B27/32
- A61J1/05
- A61J1/10
- A61M2207/00
- Y10T428/1352
- Y10T428/1383
- Y10T428/1379
- IPC, 3
- A61J1 10
- B32B1 00
- B32B27 32